30 closest matches · ranked by relevance
Relapsing-Remitting Multiple Sclerosis
Primary: Adjusted Mean Estimates for Injection-Related Adverse Event Rate Per Year in the Core Period — 70.403; 35.275 events per year — p=0.0006
Type 2 Diabetes Mellitus
Primary: Annual Rate of Change in FEV1 From Baseline to End of Study — -0.048 Liters per year
Healthy Subjects
Primary: Number of Adverse Events — 9; 4; 5; 2 AEs
Healthy Volunteers
Primary: Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) — 41.7; 33.3; 16.7; 33.3 percentage of participants
Tardive Dyskinesia
Primary: Number of Participants Monitored for Long-Term Safety of Valbenazine — 45; 107; 11 Participants
TTR-mediated Amyloidosis
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Study Drug Discontinuation — 1; 3; 2; 7 Participants
Healthy
Primary: Percentage of Subjects With Investigator Defined Drug-Related Adverse Events — 50.0; 50.0; 66.7; 50.0 Percentage of subjects
Schizophrenia
Primary: Number of Participants With Adverse Events — 19; 22; 18 participants
Healthy Volunteers
Primary: Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event — 50.0; 50.0; 33.3; 66.7 percentage of participants
Dose Finding Study
Primary: Percentage of Participants Who Experienced at Least 1 Treatment-Emergent Adverse Event — 0; 16.7; 0; 16.7 percentage of participants
Schizophrenia
Primary: Number of Participants With Adverse Events (AEs) — 5; 58; 54; 63 Participants
Multiple Sclerosis
Primary: Number of Participants With Adverse Events as a Measure of Safety and Tolerability — 100; 12; 0 Participants
Partial Epilepsy
Primary: Percent Change in Seizure Rate — -26.3 percentage of change in seizure rate
Healthy
Primary: Number of Young and Elderly Subjects With On-treatment Adverse Events by Treatment Group — 6; 3; 5; 6 Participants
Healthy
Primary: Percentage of Subjects With Drug-related Adverse Events (AEs) — 0.0; 0.0; 0.0; 5.6 Percentage of participants
Depressive Disorder, Major
Primary: Number of Participants With Treatment-Emergent Adverse Events at a Frequency Threshold of ≥5% — 258; 80; 68; 65 participants
Healthy
Primary: Unsolicited Adverse Event Reports — 3; 4 Unsolicited Adverse Event Reports
Hypertension and Chronic Heart Failure
Primary: Percentage (%) of Subjects With Treatment-Emergent Adverse Event (TEAE) Related to Study Medication (SM) - Single Ascending Dose (SAD) Period — 28; 0; 0; 0 % of subject…
Major Depressive Disorder
Primary: Incidence of Adverse Events (AEs) — 1124 Participants
Hearth Failure With Reduced Ejection Fraction (HFrEF)
Primary: Percentage of Participants on LCZ696 200 mg Bid at Month 6 — 64.6 Percentage of Participants
Healthy
Primary: Number of Treatment Related Adverse Events — 3; 4; 0; 3 Number of events
Psoriasis
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 0 Participants
Nonalcoholic Steatohepatitis
Primary: Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) — 81.0; 86.4; 81.8; 72.7 percentage of participants
Dose Finding Study
Primary: Percentage of Participants Who Experience at Least One Treatment Emergent Adverse Event (TEAE) — 16.7; 0; 50.0; 0 percentage of participants
Healthy Volunteers
Primary: Percentage of Participants Who Experience at Least One Treatment-emergent Adverse Event (TEAE) in Part 1 Single-rising Dose (SRD) — 11.1; 0; 0; 16.7 percentage of…
Schizophrenia
Primary: Number of Participants With Treatment-related Adverse Events as Assessed
Schizophrenia · Mental Disorder · Nervous System Diseases
Primary: Number of Participants With Adverse Events (AEs). — 112; 4; 112; 2 participants
Autism
Primary: Adverse Events — 2; 1; 2; 6 participants
Inhalational Anthrax
Primary: Number of Participants Who Experienced Adverse Events — 88; 27 Participants
Tourette Syndrome
Primary: Frequency of Treatment-emergent Adverse Events (TEAEs) — 20; 29; 68 Participants